Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12993061 | 0.86 | ALDH1A1 (0.51) | KDM4ESMN1; SMN2PPARGPPARDALDH1A1 | |
| SCHEMBL9811728 | 0.85 | KDM4E (0.60) | KDM4EMAOBAOC3MRGPRX4PPARG | |
| SCHEMBL13642053 | 0.84 | KDM4E (0.67) | KDM4EMAOBAOC3MRGPRX4PPARG | |
| SCHEMBL18286160 | 0.84 | KDM4E (0.57) | KDM4EMAOBMRGPRX4PPARGPPARA | |
| SCHEMBL18814688 | 0.84 | PPARG (0.50) | KDM4EPPARGPPARDPPARAALDH1A1 | |
| SCHEMBL11146060 | 0.84 | KDM4E (0.74) | KDM4EMAOBAOC3SMN1; SMN2MRGPRX4 | |
| SCHEMBL8010305 | 0.84 | ALDH1A1 (0.49) | KDM4EALDH1A1GAAPDK2MEN1 | |
| SCHEMBL4076916 | 0.84 | LMNA (0.62) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL585546 | 0.83 | KDM4E (0.68) | KDM4EMAOBAOC3MRGPRX4PPARG | |
| SCHEMBL31645913 | 0.83 | KDM4E (0.68) | KDM4EMAOBAOC3MRGPRX4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745129-A2 | COMPOUND HAVING CYCLIC STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2026-05-20 | — | — | EP | disclosed |
| EP-3682881-B1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO CO LTD (JP) | 2026-04-01 | — | — | EP | disclosed |
| US-12297187-B2 | Compound having cyclic structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-05-13 | — | — | US | disclosed |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| CN-111094255-B | Compounds having cyclic structures | 第一三共株式会社 | 2023-10-03 | — | — | CN | disclosed |
| US-11512067-B2 | Compound having cyclic structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-11-29 | — | — | US | disclosed |
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3682881-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-07-22 | — | — | EP | disclosed |
| CN-111094255-A | Compound having cyclic structure | 第一三共株式会社 | 2020-05-01 | — | — | CN | disclosed |
| US-8901319-B2 | Process for the preparation of F-series prostaglandins | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2014-12-02 | — | — | US | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| US-7674921-B2 | Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension | CAYMAN CHEMICAL COMPANY, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2125823-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-7585889-B2 | Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension | CAYMAN CHEMICAL COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| WO-2008078291-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20080146821-A1 | Internal 1,15-Lactones Of Fluprostenol And Related Prostaglandin F2a Analogs And Their Use In The Treatment Of Glaucoma And Intraocular Hypertension | MAXEY KIRK M | 2008-06-19 | — | — | US | disclosed |
| US-20080070978-A1 | Internal 1,15-Lactones Of Fluprostenol And Related Prostaglandin F2a Analogs And Their Use In The Treatment Of Glaucoma And Intraocular Hypertension | MAXEY KIRK M | 2008-03-20 | — | — | US | disclosed |
| EP-0342003-B1 | USE OF 15-KETOPROSTAGLANDIN E OR F COMPOUNDS FOR UTERINE CONTRACTION | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1993-09-08 | — | — | EP | disclosed |
| US-5185374-A | Administering to a patient ot interrupt pregnancy | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1993-02-09 | — | — | US | disclosed |
| EP-0342003-A1 | Use of 15-ketoprostaglandin E or F compounds for uterine contraction | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1989-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297187-B2 | Compound having cyclic structure | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | KDM4E 1061/4885MAOB 575/4885AOC3 1836/4885 |
| US-20080146821-A1 | Internal 1,15-Lactones Of Fluprostenol And Related Prostaglandin F2a Analogs And Their Use In The Treatment Of Glaucoma And Intraocular Hypertension | PTGIS, PTGS1, PTGIR | KDM4E 4505/4885MAOB 1968/4885AOC3 3093/4885 |
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | KDM4E 1061/4885MAOB 575/4885AOC3 1836/4885 |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | HCRTR1, HCRTR2, NPY5R | KDM4E 1260/4885MAOB 567/4885AOC3 255/4885 |
| US-20080070978-A1 | Internal 1,15-Lactones Of Fluprostenol And Related Prostaglandin F2a Analogs And Their Use In The Treatment Of Glaucoma And Intraocular Hypertension | PTGIS, PTGS1, PTGIR | KDM4E 4505/4885MAOB 1968/4885AOC3 3093/4885 |
| US-11512067-B2 | Compound having cyclic structure | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | KDM4E 1061/4885MAOB 575/4885AOC3 1836/4885 |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | KDM4E 1061/4885MAOB 575/4885AOC3 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.